Evidence map›Paper›PMID 37515656›Full record

ArticleInternational journal of hematology2023

A retrospective analysis of clinical features and treatment outcome in 21 patients with immunoglobulin M-related light-chain amyloidosis in Japan: a study from the Amyloidosis Research Committee.

Shin-Ichi Fuchida, Mizuki Ogura, Tadao Ishida, Hiroyuki Hata, Hiroshi Handa, Nagaaki Katoh, Chiaki Nakaseko, Kazutaka Sunami, Yuta Katayama, Hironobu Nobata and 5 more

Abstract read
PubMed Publisher
In one paragraph

Article in International journal of hematology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.3field-weighted citation impact, top 36% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 11 institutions in 1 country.

Shin-Ichi FuchidaDepartment of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center, 27 Shimofusa-cho, Kita-ku, Kyoto, 603-8151, Japan. sfuch0614@gaia.eonet.ne.jp.ORCID http://orcid.org/0000-0002-4147-9113
Mizuki OguraDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Tadao IshidaDepartment of Hematology, Japanese Red Cross Medical Center, Tokyo, Japan.
Hiroyuki HataDepartment of Informative Clinical Sciences, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan.
Hiroshi HandaDepartment of Hematology, Graduate School of Medicine, Gunma University, Maebashi, Japan.
Nagaaki KatohDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Chiaki NakasekoDepartment of Hematology, Faculty of Medicine, International University of Health and Welfare, Otawara, Japan.
Kazutaka SunamiDepartment of Hematology, National Hospital Organization Okayama Medical Center, Okayama, Japan.
Yuta KatayamaDepartment of Hematology, Hiroshima Red Cross and Atomic Bomb Hospital, Hiroshima, Japan.
Hironobu NobataDepartment of Nephrology and Rheumatology, Aichi Medical University, Nagakute, Japan.
Kazuiku OshiroDepartment of Hematology and Oncology, Okinawa Prefectural Nanbu Medical Center and Children's Medical Center, Okinawa, Japan.
Shinsuke IidaDepartment of Hematology and Oncology, Nagoya City University Institute of Medical and Pharmaceutical Sciences, Nagoya, Japan.
Yoshiki SekijimaDepartment of Medicine (Neurology and Rheumatology), Shinshu University School of Medicine, Matsumoto, Japan.
Hironobu NaikiDepartment of Molecular Pathology, Faculty of Medical Sciences, University of Fukui, Fukui, Japan.
Chihiro ShimazakiDepartment of Hematology, Japan Community Health care Organization, Kyoto Kuramaguchi Medical Center, 27 Shimofusa-cho, Kita-ku, Kyoto, 603-8151, Japan.
Japanese Red Cross Medical Center · JPKyoto Medical Center · JPShinshu University · JPAichi Medical University · JPGunma University · JPHiroshima Red Cross Hospital & Atomic-bomb Survivors Hospital · JPInternational University of Health and Welfare · JPKumamoto University · JPNagoya City University · JPNational Hospital Organization · JPUniversity of Fukui · JP

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

We retrospectively gathered data of 21 patients (13 male and 8 female; median age 65 years) diagnosed with immunoglobulin M (IgM)-related light-chain (AL) amyloidosis in Japan to investigate characteristics of IgM-AL amyloidosis and its optimal treatment strategy. Median IgM and difference free light chain (FLC) at diagnosis were 1257 mg/dl and 34.3 mg/l, respectively. Organ involvement was observed in the heart in 7 patients (33%), kidneys in 15 (71%), and lymph nodes in 5 (24%). Initial treatments were melphalan/dexamethasone in 7 patients, bortezomib/cyclophosphamide/dexamethasone in 3, autologous stem cell transplantation in 3, rituximab/bendamustine in 1, other in 3, and none in 4. Hematological responses among 15 evaluable patients were as follows: 3 reached complete response (CR), 4 partial response (PR), and 1 very good PR (VGPR), making the overall response rate of PR or better 40%. Median overall survival (OS) was 14.0 months and 1-year OS was 71.4%. Prognosis was significantly poorer in patients with cardiac involvement than those with non-cardiac involvement (1-year OS 27.8% vs. 85.7%, p = 0.0468). The involved FLC value was low in several patients and therapeutic response was difficult to assess. Further study is necessary to determine the optimal treatment for IgM-AL amyloidosis.

Indexed as

AmyloidosisHematopoietic Stem Cell TransplantationImmunoglobulin Light-chain AmyloidosisAgedBortezomibDexamethasoneFemaleHumansImmunoglobulin Light ChainsImmunoglobulin MJapanMaleRetrospective StudiesTransplantation, AutologousTreatment OutcomeBortezomibDexamethasoneImmunoglobulin Light ChainsImmunoglobulin MAutologous transplantationCardiac amyloidosisChemotherapyFree light chain (FLC)IgM-AL amyloidosis

Identifiers

PMID37515656
OpenAlexW4385380383

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.